Brokers Offer Predictions for LRMR FY2025 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Lifesci Capital issued their FY2025 EPS estimates for shares of Larimar Therapeutics in a report released on Tuesday, February 24th. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings per share of ($1.70) for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q4 2025 earnings at ($0.41) EPS.

LRMR has been the subject of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Larimar Therapeutics in a report on Wednesday. Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, January 22nd. Finally, Citigroup raised their price objective on shares of Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $16.14.

Larimar Therapeutics Trading Up 61.2%

NASDAQ LRMR opened at $5.95 on Thursday. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.42. The company has a 50 day moving average of $3.49 and a 200-day moving average of $3.77. The firm has a market cap of $492.54 million, a price-to-earnings ratio of -3.08 and a beta of 1.00.

Institutional Trading of Larimar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRMR. BNP Paribas Financial Markets lifted its position in Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after purchasing an additional 4,376 shares during the period. Savant Capital LLC acquired a new stake in shares of Larimar Therapeutics during the 2nd quarter worth approximately $39,000. B.O.S.S. Retirement Advisors LLC bought a new stake in shares of Larimar Therapeutics during the third quarter worth approximately $41,000. Coldstream Capital Management Inc. acquired a new position in Larimar Therapeutics in the third quarter valued at approximately $57,000. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Larimar Therapeutics by 33.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock worth $59,000 after acquiring an additional 4,619 shares during the period. 91.92% of the stock is owned by institutional investors.

Key Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, management reiterated a planned BLA submission in June 2026 and target U.S. launch in H1 2027 if approved — a development that materially de-risks the program and supports accelerated approval prospects. Article Title
• Positive Sentiment: Several analysts upgraded or raised price targets (Citigroup to $14 buy, Wedbush reaffirmed outperform with $11 PT, Lifesci Capital to strong-buy), signaling institutional bullishness that can support upside momentum. Article Title
• Neutral Sentiment: Unusual options activity: traders bought ~3,744 calls (≈456% above typical daily call volume), indicating speculative/leveraged bullish positioning that may amplify intraday moves but is not a fundamental change.
• Neutral Sentiment: Media coverage and headlines about the FDA action drove a sharp pre-market surge and massive intraday trading volume (recent reports show daily volume far above the stock’s average), increasing volatility and short-term liquidity. Article Title
• Negative Sentiment: Larimar filed a proposed underwritten public offering of $75 million of common stock (with an underwriter option for an additional $11.25M) — a sizable raise relative to its market cap that introduces near-term dilution risk and can pressure the share price until proceeds are deployed. The offering is subject to market conditions and may create volatility. Article Title

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.